Assessing Tablet-Sticking Propensity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Tablet-Sticking Propensity
The authors designed an upper punch with a removable punch tip to determine a tablet formulation's propensity to stick by weighing the mass of powder adhered to the punch tip.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 57-62


Figure 7: Sticking profiles for prototype and commercially available ibuprofen formulations.
Benchmarking sticking of a new ibuprofen formulation. A prototype ibuprofen formulation was tested alongside three commercially available ibuprofen formulations to quantify sticking risk before scale-up. The prototype formulation contained a 50% w/w level of ibuprofen and 5% w/w talc as the tableting lubricant. After 100 compressions, the prototype formulation had about 1500 g of powder adhered to the punch tip. The commercial ibuprofen formulations had lower sticking: Albemarle had the most, followed by BASF and Advil (See Figure 7). Using Advil as the gold-standard benchmark, the prototype formulation was deemed to be unsuitable for product scale-up without reformulation. The high level of sticking for the prototype ibuprofen formulation was attributed to literature reports of talc as a suboptimal tableting lubricant for sticky formulations (7, 8), in addition to ibuprofen's notorious propensity to stick. This quantitative assessment shows the benefit of testing prototype formulations and benchmarking alongside formulations known to (or not to) exhibit sticking behavior. Thus, unsuitable formulations can be flagged quickly during drug product design.

Conclusion

The simple method of using a removable punch tip is capable of quantitatively measuring sticking for formulations containing various levels of tableting lubricant and various grades and concentrations of sticky ingredients. This tool can be used to screen tableting formulations during drug-product design to optimize formulation composition, and potentially to study the effect of sticking on tableting process parameters (e.g., tableting speed and compression force) and tooling design features (e.g., metal composition, surface roughness, shape, curvature, and embossing).

Acknowledgments

The authors thank MDC Associates for assisting with the design and fabrication of the custom punch. They thank Gregory (Scott) Goeken, scientist, and John Kresevic, senior principal scientist, both at Pfizer, for providing the prototype and commercial ibuprofen formulation samples.

References

1. M. Roberts et al., J. Pharm. Pharmacol. 56 (3), 299–305 (2004).

2. T.S. McDermott et al., Powder Technol. 212 (1), 240–252 (2011).

3. D. Simmons, poster at the 12th Annual American Association of Pharmaceutical Scientists—Northeast Regional Discussion Group (Rocky Hill, CT, 2009).

4. J.J. Wang et al., J. Pharm. Sci. 93 (2), 407–417 (2004).

5. Y. Cheng et al., Proceedings of AICHE Annual Conference (Orlando, FL, 2006), pp. 1–13.

6. F. Waimer et al., Pharm. Dev. Technol. 4 (3), 359–367 (1999).

7. M. Bose, A. Sakr, and A. Warner, Pharm. Industrie 55 (5), 519–522 (1993).

8. A. Delacourte et al., Drug Dev. Ind. Pharm. 19 (9), 1047–1060 (1993).

What would you do differently? Email your thoughts about this paper to
and we may post them on http://PharmTech.com/.

Matthew P. Mullarney* is a principal scientist, Bruce C. MacDonald is a scientist, and Allan Hutchins is a laboratory technician, all at Pfizer, Eastern Point Road, Groton, CT 06340, tel. 860.715.4139, fax 860.441.3972,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here